PDCD1 and hepatocellular carcinoma: Our completed phase 1 study and long-term follow-up of the sequential combination use of ropeg at a tolerable, high dose of 450 μg followed by anti-PD-1 antibody nivolumab at low doses demonstrate the utility of this regimen as adjuvant therapy following hepatic resection of HBV-related HCC.